ClinicalTrials.gg
CompletedNCT05889299Updated May 11, 2026

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

A Phase 1 interventional study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Omeros Corporation. Completed at 1 site in Ukraine. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Omeros Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled Dec 2022, registered May 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Read the detailed description

This is a Phase 1b, proof of concept, open-label, uncontrolled study. The primary objective is to assess the safety and tolerability of OMS906 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). The study evaluated 3 dosing regimens: (1) 5 mg/kg SC administered every 4 weeks (Q4W), (2) 5 mg/kg IV administered once followed by administration of additional doses of 5 mg/kg IV at the occurrence of protocol-defined subclinical breakthrough hemolysis, and (3) 8 mg/kg IV every 8 weeks (Q8W) on a fixed-dosing (FD) schedule

02

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • PNH
03

In context

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

This study's enrollment of 15 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.

Browse Hemoglobinuria, Paroxysmal studies →

Lead sponsor

Omeros Corporation is the lead sponsor of 25 studies on the registry; 1 is open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of PNH by flow cytometry with PNH clone size of >10% RBCs and/or granulocytes.
  2. Male or female adults 18 years and older.
  3. Competent to provide consent and completed procedures.
  4. Patients who are not receiving complement inhibitor treatment or, alternatively, patients currently treated with eculizumab or ravulizumab with an inadequate response to treatment defined as a \<10.5 g/dL. Patients receiving eculizumab or ravulizumab must be on stable doses for at least 6 months.
  5. Hemoglobin level \<10.5 g/dL at screening and baseline.
  6. Lactate dehydrogenase >1.5 (ULN) for patients not receiving eculizumab or ravulizumab.
  7. Female patients of (CBP) must have a negative serum test at screening and highly sensitive urine pregnancy test prior to each dose of OMS906.
  8. Females must use highly effective to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug.
  9. Males must use highly effective birth control with a female partner to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug.
  10. Have received vaccination for Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae (if locally available). Patients who have not received these vaccinations at the time of screening may be vaccinated at any time prior to 2 weeks before the first study drug administration. Patients enrolled in the study at the time of Amendment 02 may receive S. pneumoniae and H. influenzae vaccinations, if not already vaccinated, at their next scheduled visit.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any complement pathway inhibitor except eculizumab or ravulizumab within the 6 months prior to screening.
  2. For patients not receiving eculizumab or ravulizumab at the time of screening: receipt of eculizumab within 8 weeks prior to screening or receipt of ravulizumab within 24 weeks prior to screening.
  3. History of major organ transplant or hematopoietic stem cell/bone marrow transplant.
  4. Reticulocyte count \<100,000 /µL, transfusion-free count \<30,000/µL or \<500 cells/µL at screening.
  5. Anemia attributable to any other medical condition apart from PNH.
  6. Elevation of liver function tests, defined as total >2×, direct bilirubin >1.5xULN, and elevated transaminases, (ALT) or aspartate transaminase (AST), >2×ULN unless due to PNH related hemolysis.
  7. History of any severe reactions to other monoclonal antibodies or included in the OMS906 preparation.
  8. Significant active bacterial, fungal, or viral infection within the 2 weeks of OMS906 drug initiation, including COVID-19 infection.
  9. History of primary or secondary immunodeficiency or complement deficiency.
  10. Have , or untreated infection.
  11. History of splenectomy.
  12. History or prior bacterial meningitis or N. meningitidis infection.
  13. Patients on agents such as but not limited to cyclosporine, mycophenolate mofetil (MMF), tacrolimus, cyclophosphamide, or methotrexate less than 8 weeks prior to first treatment with OMS906 unless on a stable regimen for at least 3 months prior to screening.
  14. Patients who require recurrent short courses of systemic (i.e., >4 short courses per year of >2 weeks in duration per course).
  15. Pregnant, planning to become pregnant, or nursing female patients.
  16. Recent surgery requiring general anesthesia within the 2 weeks prior to screening or expected to have surgery requiring general anesthesia during the treatment periods.
  17. History of any medical, neurologic, or psychiatric disorder that in the opinion of the investigator would make the patient unsuitable for participation in the study.
  18. Treatment with any medicinal product or investigational device within the 30 days (or within 5x its half-life in days, whichever is the longer period) prior to screening or participation in another concurrent clinical trial involving a therapeutic intervention. Participation in observational studies and/or registry studies is permitted.
  19. Unable or unwilling to comply with the requirements of the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    OMS906 study drug administration in three phases

    1. 5 mg/kg SC administered every 4 weeks (Q4W), 2. 5 mg/kg IV administered once followed by administration of additional doses of 5 mg/kg IV at the occurrence of protocol-defined subclinical breakthrough hemolysis, and 3.) 8 mg/kg IV every 8 weeks (Q8W) on a fixed-dosing (FD) schedule

    Biological: OMS906

Interventions

  • BiologicalOMS906

    Biological: OMS906

    Also known as: zaltenibart

06

What researchers measure

Primary outcomes

  1. To Assess the Overall Safety and Tolerability of Zaltenibart (OMS906) Administration in PNH patients

    Number and % of participants with Treatment-emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0, including abnormalities in laboratory measures, ECGs and physical examinations.

    Time frame: 48 weeks

Secondary outcomes

  1. Mean Lactate Dehydrogenase (LDH) change from baseline

    Mean Lactate Dehydrogenase (LDH) change from baseline (Only patients not receiving complement inhibitor treatment)

    Time frame: 48 weeks

  2. Mean change of hemoglobin (Hgb)

    To assess preliminary efficacy by the effect on hemolysis and anemia measured by hemoglobin (Hgb).

    Time frame: 48 weeks

  3. Time to subclinical breakthrough hemolysis post-treatment

    Time (in days) to subclinical breakthrough hemolysis during the 5 mg/kg IV on demand period.

    Time frame: 48 weeks

  4. Mean change from baseline in absolute reticulocyte count

    Individual patient changes from baseline in absolute reticulocyte counts

    Time frame: 48 weeks

  5. Transfusion requirements

    Mean change from baseline in transfusion frequency from the 6-month period prior to the first OMS906 dose to the end of the study

    Time frame: -24 weeks to 48 weeks

  6. Transfusion free

    Proportion of patients who are transfusion free from Week 4 through the end of the study

    Time frame: Week 4 to Week 48

  7. Proportion of breakthrough hemolysis

    Proportion of patients experiencing breakthrough hemolysis during the 5 mg/kg Q4W SC treatment period.

    Time frame: 48 weeks

  8. Proportion of breakthrough hemolysis

    Proportion of patients experiencing breakthrough hemolysis during the 8 mg/kg Q4W IV treatment period

    Time frame: 48 weeks

  9. Incidence of patients with hemoglobin increase ≥ 2.0 g/dL from baseline

    Number and % of participants with hemoglobin increase ≥ 2.0 g/dL from baseline

    Time frame: 48 weeks

  10. Incidence of patients with hemoglobin increase ≥ 12.0 g/dL from baseline

    Number and % of participants with hemoglobin increase ≥ 12.0 g/dL from baseline

    Time frame: 48 weeks

  11. Pharmacokinetics (PK) of multiple-dose administration of OMS906: Cmax

    Maximum concentration (Cmax) of observed OMS906 plasma concentration by OMS906 dosing regimen.

    Time frame: 48 weeks

  12. Pharmacokinetics (PK) of multiple-dose administration of OMS906: AUC

    Area under the plasma concentration versus time curve (AUC)

    Time frame: 48 weeks

  13. Free Mannan-binding lectin-associated Serine protease 3 concentration

    Free MASP-3 serum concentrations by dosing regimen following the first dose and repeated doses

    Time frame: 48 weeks

  14. Mature Complement Factor Concentration

    Mature Complement Factor D (CFD) concentrations by dosing regimen following the first dose and repeated doses

    Time frame: 48 weeks

  15. Total Mannan-Binding Lectin-Associated Serine Protease 3 (MASP-3) Concentration

    Total MASP-3 serum concentrations by OMS906 dosing regimen following first dose and repeated doses

    Time frame: 48 weeks

  16. OMS906 anti-drug antibodies (ADA)

    Number of patients with measurable ADA

    Time frame: 48 weeks

07

Study locations

1 site
  • Omeros Investigational Site
    Kyiv, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Nov 2025, 34 months.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2023
First posted
Jun 5, 2023
StartActual
Dec 9, 2022
Primary completionActual
Nov 3, 2025
CompletionActual
Nov 3, 2025
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05889299
Lead sponsor
Omeros Corporation
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Dec 9, 2022
Primary completion
Nov 3, 2025
Completion
Nov 3, 2025
Last update
May 11, 2026

Study contacts

Steve Whitaker, MD
study director · Omeros Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zaltenibart

Start the discussion